Literature DB >> 14605832

Increased 14-3-3 immunoreactivity in glial elements in patients with multiple sclerosis.

Yasuhiro Kawamoto1, Ichiro Akiguchi, Gábor G Kovács, Helga Flicker, Herbert Budka.   

Abstract

14-3-3 proteins have been shown to be increased in the cerebrospinal fluid from patients with several kinds of neurological diseases, including multiple sclerosis (MS). To investigate whether 14-3-3 proteins are closely related to the pathogenesis of MS, we performed immunohistochemical studies for 14-3-3 in autopsied brains from ten patients with MS, five patients with progressive multifocal leukoencephalopathy (PML), and seven normal control subjects. Formalin-fixed, paraffin-embedded sections from all cases were immunostained with a specific anti-14-3-3 antibody, and some sections from the MS cases were double-immunostained with antibodies raised against 14-3-3 and glial markers. In the normal control brains, 14-3-3 immunoreactivity was localized mainly in the neuronal somata and processes, and some glial cells showed only weak immunoreactivity. In the plaque lesions from the MS cases, the astrocytes and oligodendrocytes were intensely immunostained, and strong immunoreactivity was also found in some microglia and macrophages, most of which were located in the perivascular areas. In the PML brains, a similar immunolabeling pattern was observed in the demyelinated lesions, in which the astrocytes and oligodendrocytes exhibited dense 14-3-3 immunoreactivity. Our results suggest that 14-3-3 may be up-regulated in the glial cells, especially in astrocytes and oligodendrocytes, in patients with MS or PML. The exaggerated 14-3-3 accumulation in these glial elements may be associated with the pathogenesis of both demyelinating disorders.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14605832     DOI: 10.1007/s00401-003-0785-z

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  4 in total

1.  Immunocytochemical detection of 14-3-3 in primary nervous system tumors.

Authors:  Wei-Dong Cao; Xiang Zhang; Jian-Ning Zhang; Zhi-Jun Yang; Hai-Ning Zhen; Guang Cheng; Bian Li; Dakuan Gao
Journal:  J Neurooncol       Date:  2005-11-15       Impact factor: 4.130

Review 2.  Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making.

Authors:  Violaine K Harris; Saud A Sadiq
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

3.  Glial cell type-specific subcellular localization of 14-3-3 zeta: an implication for JCV tropism.

Authors:  Shivani Lamba; Veerasamy Ravichandran; Eugene O Major
Journal:  Glia       Date:  2009-07       Impact factor: 7.452

Review 4.  Are cerebrospinal fluid biomarkers useful in predicting the prognosis of multiple sclerosis patients?

Authors:  Alberto Gajofatto; Matilde Bongianni; Gianluigi Zanusso; Maria Donata Benedetti; Salvatore Monaco
Journal:  Int J Mol Sci       Date:  2011-11-16       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.